Royalty Pharma plc (NASDAQ:RPRX) Receives Consensus Recommendation of “Buy” from Brokerages

Royalty Pharma plc (NASDAQ:RPRX) has been assigned an average rating of “Buy” from the seven brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $41.67.

A number of research firms have issued reports on RPRX. Citigroup reduced their target price on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, October 25th. TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. Finally, StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Brooklyn Investment Group boosted its holdings in Royalty Pharma by 1,006.9% during the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 876 shares during the period. Blue Trust Inc. lifted its position in shares of Royalty Pharma by 362.7% during the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 943 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Royalty Pharma during the 3rd quarter valued at approximately $61,000. GAMMA Investing LLC grew its holdings in Royalty Pharma by 31.4% in the 4th quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 590 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in Royalty Pharma by 32.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 655 shares during the period. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Stock Down 0.6 %

Shares of Royalty Pharma stock opened at $30.75 on Friday. The firm has a market cap of $18.12 billion, a price-to-earnings ratio of 15.93 and a beta of 0.47. The stock has a 50-day simple moving average of $26.31 and a 200-day simple moving average of $27.18. Royalty Pharma has a 52-week low of $24.05 and a 52-week high of $31.66. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54.

Royalty Pharma Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 21st will be issued a dividend of $0.22 per share. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a dividend yield of 2.86%. The ex-dividend date of this dividend is Friday, February 21st. Royalty Pharma’s dividend payout ratio is currently 43.52%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.